Cover image of the article: A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast Cancer

Image Credit:Int J Cancer Manag

A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast Cancer

Authors

Hamidreza Ramezanpour1,*, S Setayeshi1, ME Akbari2
1Amirkabir University of Technology, Tehran, Iran
2Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Author: Corresponding author: Hamidreza Ramezanpour, Amirkabir University of Technology, Tehran, Iran, Tel: +98-5118543648, E-mail: Email: h.ramezanpour@aut.ac.ir

International Journal of Cancer Management:Vol. 4, issue 4; e80750
Published online:Dec 30, 2011
Article type:Research Article
Received:May 28, 2011
Accepted:Aug 15, 2011
How to Cite:Ramezanpour H, Setayeshi S, Akbari M. A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast Cancer. Int J Cancer Manag. 2011;4(4):e80750. doi:

Abstract

Background: Determining the optimal and effective scheme for administrating the chemotherapy agents in breast cancer is the main goal of this scientific research. The most important issue here is the amount of drug or radiation administrated in chemotherapy and radiotherapy for increasing patient's survival. This is because in these cases, the therapy not only kills the tumor cells, but also kills some of the healthy tissues and causes serious damages. In this paper we investigate optimal drug scheduling effect for breast cancer model which consist of nonlinear ordinary differential time-delay equations.

Methods: In this paper, a mathematical model of breast cancer tumors is discussed and then optimal control theory is applied to find out the optimal drug adjustment as an input control of system. Finally we use Sensitivity Approach (SA) to solve the optimal control problem.

Results: The goal of this paper is to determine optimal and effective scheme for administering the chemotherapy agent, so that the tumor is eradicated, while the immune systems remains above a suitable level. Simulation results confirm the effectiveness of our proposed procedure.

Conclusion: In this paper a new scheme is proposed to design a therapy protocol for chemotherapy in Breast Cancer. In contrast to traditional pulse drug delivery, a continuous process is offered and optimized, according to the optimal control theory for time-delay systems.

Highlights

Fulltext

The Full text is available in PDF.

Copyright

© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

12
May
2018
Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study

Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study

Amir Shahram Yousefi Kashi,
Rezvan Montazeri,
Afshin Rakhsha

Yousefi Kashi AS, Montazeri R, Rakhsha A. Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study. Int J Cancer Manag. 2018;11(5):e67739. doi: https://doi.org/10.5812/ijcm.67739

25
Apr
2026
Breast Tumor Response & Axillary Clearance After Neoadjuvant Chemotherapy

Breast Tumor Response & Axillary Clearance After Neoadjuvant Chemotherapy

Mahdis Bayat,
Hossein Hatami,
Mohammad Esmaeil Akbari

Bayat M, Hatami H, Akbari ME. Breast Tumor Response & Axillary Clearance After Neoadjuvant Chemotherapy. Int J Cancer Manag. 2026;19(1):e170019. doi: https://doi.org/10.5812/ijcm-170019

12
May
2018
Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study

Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study

Asiie Olfatbakhsh,
Hoda Tafazzoli-Harandi,
Safa Najafi,
Esmat Al Sadat Hashemi,
Fateme Sari,
Parisa Mokhtari Hesari
,et al.

Olfatbakhsh A, Tafazzoli-Harandi H, Najafi S, Hashemi EAS, Sari F, et al. Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study. Int J Cancer Manag. 2018;11(5):e60098. doi: https://doi.org/10.5812/ijcm.60098

20
Dec
2023
Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review

Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review

Mohammad Akbari,
Maryam Seyednezhad,
Saeed Heidari,
Mohammad Moradi-joo

Akbari M, Seyednezhad M, Heidari S, Moradi-joo M. Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review. Int J Cancer Manag. 2023;16(1):e142814. doi: https://doi.org/10.5812/ijcm-142814

30
Dec
2024
Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients

Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients

Mehdi Cheraghi,
Ensiyeh Bahadoran,
Maryam Masoomi,
Navid Mohammadi

Cheraghi M, Bahadoran E, Masoomi M, Mohammadi N. Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients. J Inflamm Dis. 2024;28(4):e154396. doi: https://doi.org/10.69107/jid-154396

More by these authors

Hamidreza RamezanpourPubMedScholar
S SetayeshiPubMedScholar
ME AkbariPubMedScholar
Share
Cited by
Metrics